Impact of Everolimus and Ciclosporin Cytomegalovirus (CMV) replication and disease of pediatric kidney allograft recipients.

Trial Profile

Impact of Everolimus and Ciclosporin Cytomegalovirus (CMV) replication and disease of pediatric kidney allograft recipients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2015 New trial record
    • 27 Nov 2015 Results published in the American Journal of Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top